Topical Bevacizumab 0.05% Eye Drops for Preventing Recurrent Pterygium, A Randomized, Double-masked, Controlled Trial
Phase 3
Recruiting
- Conditions
- rate of recurrence after primary pterygium removalNumber of participants with adverse events as a measure of safety and tolerabilitypterygiumrecurrent pterygiumbevacizumabVEGFanti-
- Registration Number
- TCTR20110000018
- Lead Sponsor
- Chulalongkorn university
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
* Patients who are diagnosed with primary pterygium and plan for pterygium excision with bare sclera by single surgeon. (G.N.)
* Patients with pterygium who understand and can follow the study protocol.
* Patients of age more than 30 years
Exclusion Criteria
* Patients who have corneal melt, corneal epitheliopathy, abnormal corneal epithelial wound healing.
* Patients who are pregnancy or lactation.
* Patients who have a history of allergy to bevacizumab.
* Patients who have a history of allergy to steroid eye drops
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method